TriVascular Technologies, which markets the smallest and most versatile stent grafts for endovascular aortic repair, raised $78 million by offering 6.5 million shares at $12, below the range of $13 to $15. TriVascular Technologies will list on the NASDAQ under the symbol TRIV. The company initially filed confidentially on December 16, 2013. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.
